ArticleCancer discovery2022
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 98 citations in OpenAlex.
- Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.bioRxiv : the preprint server for biology · 2026Article
- LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.Cancer discovery · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- Targeting mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases.Nature reviews. Molecular cell biology · 2026Review
- Inhibiting SHP2 improves ventricular remodeling by restoring AMPK phosphorylation and mitochondrial homeostasis.Cell communication and signaling : CCS · 2026Article
- Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas.Life science alliance · 2025Article
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming.Cell death & disease · 2025Review
- Targeting tumor-associated neutrophils: A promising strategy in lung cancer immunotherapy.Cancer pathogenesis and therapy · 2025Review
- Targeting neutrophils for cancer therapy.Nature reviews. Drug discovery · 2025Review
- Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations.Cancers · 2025Review
- Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025Review
- A silence catalyst: CCL5-mediated intercellular communication in cancer.Archives of toxicology · 2025Review
- Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation.Scientific reports · 2025Article
- Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancreatic cancer.Journal for immunotherapy of cancer · 2025Article
- Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies.Cancers · 2025Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Kwan Ho Tang *Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York. benjamin.neel@nyulangone.org kwok-kin.wong@nyulangone.org khhtang@gmail.com.ORCID 0000-0001-7729-5159
Shuai Li *Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.
Alireza Khodadadi-JamayranApplied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, New York.ORCID 0000-0003-2495-7504
Jayu JenLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0002-0926-9984
Han HanLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.
Kayla GuidryLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.
Ting ChenLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0003-1725-7956
Yuan HaoApplied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, New York.
Carmine FedeleLaura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.
John A ZebalaSyntrix Pharmaceuticals, Auburn, Washington.ORCID 0000-0002-3581-6750
Dean Y MaedaSyntrix Pharmaceuticals, Auburn, Washington.ORCID 0000-0002-9304-6846
James G ChristensenMirati Therapeutics, Inc., San Diego, California.
Peter OlsonMirati Therapeutics, Inc., San Diego, California.
Argus AthanasMonoceros Biosystems, Inc., San Diego, California.
Cynthia A LoomisDepartment of Pathology, New York University Grossman School of Medicine, New York, New York.
Aristotelis TsirigosApplied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, New York.ORCID 0000-0002-7512-8477
Kwok-Kin Wong *Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York. benjamin.neel@nyulangone.org kwok-kin.wong@nyulangone.org khhtang@gmail.com.
Benjamin G Neel *Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, New York. benjamin.neel@nyulangone.org kwok-kin.wong@nyulangone.org khhtang@gmail.com.
NYU Langone Health · USNew York University · USMirati Therapeutics (United States) · USSyntrix Biosystems (United States) · USOracle (United States) · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MThe impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2019 to 2026
$17.0MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MSIGNAL TRANSDUCTION BY NON-TRANSMEMBRANE PTPSR01CA049152 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEEL, BENJAMIN G. · 1989 to 2020
$4.4MSignal Transduction by Non-transmembrane PTPsR37CA049152 · NCI · UNIVERSITY HEALTH NETWORK · PI NEEL, BENJAMIN G. · 2004 to 2013
$4.0MTargeting Epigenetic Heterogeneity in Pediatric T cell leukemia: Epi-Clones as Drivers of ChemoresistanceR01CA252239 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 2021 to 2026
$3.7MResponse and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung CancerR01CA248896 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEEL, BENJAMIN G., WONG, KWOK KIN · 2021 to 2025
$3.4MMultispectral imaging & analysis of intact tissue sections w/ the Perkin Elmer VectraS10OD021747 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOOMIS, CYNTHIA A · 2016 to 2016
$359kNCI NIH HHS P01 CA229086NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA049152NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA248896NCI NIH HHS R01 CA252239NCI NIH HHS R37 CA049152NIH HHS S10 OD021747
Abstract
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is could influence the tumor microenvironment. We found that SHP2i treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion, and promoted B and T lymphocyte infiltration in
Indexed as
AnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorEnzyme InhibitorsHumansLung NeoplasmsMaleMiceMice, Inbred C57BLProtein Tyrosine Phosphatase, Non-Receptor Type 11Receptors, Interleukin-8BTumor MicroenvironmentXenograft Model Antitumor AssaysAntineoplastic AgentsCXCR2 protein, humanEnzyme InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanReceptors, Interleukin-8B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.